No Data
Most pharmaceutical stocks rose, with Tongyuan Kangyi Medicine (02410) up 18.46%. Institutions pointed out that the policy trend of medical insurance funds supporting innovative drugs will not change.
Jingwu Cai Xun | Most pharmaceutical stocks rose, with Tongyuan Kang Medicine (02410) up 18.46%, Keji Pharmaceutical (02171) up 13.86%, Heyu (02256) up 11.79%, Cloud Peak Xin Yao (01952) up 10.31%, cansinobio (06185) up 7.48%. Zhong Yin International stated that benefiting from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity industry, is expected to outperform the market. The bank believes that the performance of the macroeconomy is closely related to the revenue and expenditure of medical insurance funds and medical health consumer spending. As policy focus shifts to stimulating the economy, the bank believes that medical industry
TYK MEDICINES-B: Interim Report 2024
Tongyuan Kang Pharmaceutical-B (02410.HK) applies for full circulation of H shares.
On September 13, Gelonhui announced that on September 13, 2024, the company has submitted an application to the China Securities Regulatory Commission to convert 0.174 billion shares of non-listed shares into H shares and list these shares on the Hong Kong Stock Exchange. After obtaining the record and/or approval from all relevant regulatory institutions (including but not limited to the China Securities Regulatory Commission and the Hong Kong Stock Exchange) and complying with all applicable laws, regulations, and rules, the non-listed shares will be converted into H shares and eligible for trading on the main board of the Hong Kong Stock Exchange.
[IPO Monthly Report] The threshold for "18C" is lowered, and midea group co., ltd has succeeded in the Hong Kong IPO market in August and is preparing for an outbreak.
In August, there were 3 new listings in the Hong Kong IPO market. Although this number seems relatively quiet compared to the 10 in July, the performance in August this year is considered positive when compared to August 2023, when no new listings were made.
TYK Medicines Logs Wider Attributable Loss in H1
Same source Kang pharmaceuticals-B (02410.HK) R&D costs for the first half of the year were 0.138 billion yuan, an increase of 15.3% compared to the same period last year.
Guolonghui, August 30th, Tongyuan-Kang Pharmaceutical-B (02410.HK) announced that for the six months ended June 30, 2024 and 2023, the Group did not generate any revenue. R&D costs for the period amounted to RMB 137,758,000, an increase of 15.3% year-on-year. This increase was mainly attributed to an increase in experimental and testing expenses, especially those related to the development of core products. The loss for the reporting period increased by 26.3% from RMB 173,849,000 for the six months ended June 30, 2023 to RMB XXX for the six months ended June 30, 2024.
